Delving into the Latest Updates on Terbutaline Sulfate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Terbutaline, Terbutaline Sulfate Granules, Terbutaline Sulfate Nebuliser

+ [20]

Target

β2-adrenergic receptor

Action

agonists

Mechanism

β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesRespiratory Diseases

Active Indication

Bronchial SpasmBronchitisAsthma+ [5]

Inactive Indication

Asthma, Exercise-InducedEosinophilia, FamilialHypoglycemia+ [1]

Originator Organization

Sanofi

Active Organization

AstraZeneca Pharmaceuticals Co. Ltd.AstraZeneca KK

ANI Pharmaceuticals, Inc.

+ [1]

Inactive Organization

Vectura Group Ltd.

AstraZeneca PLC

Sanofi-Aventis U.S. LLC

Drug Highest PhaseApproved

First Approval Date

Japan (08 Aug 1973),

AsthmaAsthmatic bronchitisBronchiectasis+ [2]

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC12H19NO3

InChIKeyXWTYSIMOBUGWOL-UHFFFAOYSA-N

CAS Registry23031-25-6

View All Structures (2)

The overall aim in Part 1 is to compare the pharmacokinetic (PK)/pharmacodynamics (PD) relationship in intravenous (IV) versus subcutaneous (SQ) terbutaline sulfate to identify the optimal IV dosing range for use in Part 2.
The overall aim in Part 2 is to evaluate the optimal IV dosing of terbutaline sulfate based on PD response and safety data.

Start Date07 Jul 2023

Sponsor / Collaborator

Duke University

[+2]

NCT05494307

/ Unknown statusPhase 2IIT

A Multicenter Randomized Trial of Second Line Treatment for Corticosteroid-Resistant or Relapsed Immune Thrombocytopenia: Combined Terbutaline and Danazol Versus Danazol Monotherapy

A randomized, open-label, multicenter study to compare the efficacy and safety of terbutaline plus danazol compared to danazol monotherapy for the second-line treatment of adults with corticosteroid-resistant or relapsed primary immune thrombocytopenia (ITP).

Start Date01 Sep 2022

Sponsor / Collaborator

Peking University People's Hospital

100 Clinical Results associated with Terbutaline Sulfate

Login to view more data

100 Translational Medicine associated with Terbutaline Sulfate

Login to view more data

100 Patents (Medical) associated with Terbutaline Sulfate

Login to view more data

6,107

Literatures (Medical) associated with Terbutaline Sulfate

01 Feb 2025·Chromatographia

Development and Validation of Confirmatory Quantitative and Screening Methods for 63 Prohibited Substances in Horse Urine Using LC–MS/MS

Author: Goktas, Eylem Funda ; Kabil, Erol

Abstract: The number of potentially abused substances in horse racing is very large and it is not easy to analyze the full range.To facilitate the analyses of substances of abuse, a method has been developed for 63 substances in horse urine using liquid chromatog.-tandem mass spectrometry.The developed method has been validated according to the 2021/808/EC and AORC criteria.The horse urine samples were extracted after enzymic hydrolysis via a C8-BCX SPE cartridge with an automated SPE and analyzed by LC-MS/MS.According to the validation study results, the within-laboratory reproducibility CV was no more than 13.9% and the average recoveries ranged from 90.71 to 117.94% for repeatability and reproducibility.The decision limits (CCα) for quant. anal. and detection capabilities (CCβ) for qual. screening were close to the targeted limit for each substance.The results of the present study showed that the method was able to perform quant. analyses of 54 substances and screening analyses of 9 substances (total 63) in horse urine and that the results were valid and applicable.The validated method was successfully applied to five proficiency tests and three suspected samples.

01 Feb 2025·The Journal of Emergency Medicine

A Novel Use of Terbutaline: Persistent Genital Arousal Disorder in the Emergency Department

Article

Author: Abernathy, Bobby ; Murray, Kelly A ; Luth, James ; Luth, Sadaf

BACKGROUNDPersistent genital arousal disorder/genito-pelvic dysesthesia (PGAD/GPD) is a highly distressing, multifactorial disorder characterized by persistent unwanted physiologic genital arousal in the absence of sexual desire. This poorly understood disorder is thought to be derived from a complex dysregulation of biopsychosocial factors with common underlying neurological dysfunction that has yet to be adequately studied. With frequently evolving diagnostic criteria, lack of a standardized treatment algorithm, and few evidence-based treatment options, this disease is largely unrecognized and difficult to treat once identified.CASE REPORTA 25-year-old woman presented to the Emergency Department (ED) with persistent and refractory symptoms of genital arousal not responsive to previously documented treatments, and the novel use of a β-adrenergic agent, terbutaline, leading to cessation of symptoms. With her initial presentation, lorazepam, haloperidol, and viscous lidocaine intravaginally provided relief for approximately 24 h until the patient returned. At her subsequent presentation, the patient received additional doses of lorazepam and intravaginal lidocaine, as well as consults with Urology and Obstetrics and Gynecology. Her symptoms eventually ceased by administration of terbutaline. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: Although presentation of PGAD to the ED is rare, emergency physicians should be prepared with treatment options to assist patients with this distressing diagnosis. This case highlights the novel use of terbutaline, a β-agonist, in cessation of PGAD symptoms when first-line benzodiazepines and antipsychotics fail.

01 Feb 2025·Analytical and Bioanalytical Chemistry

LC-HRMS screening procedure for the detection of 11 different classes of prohibited substances in dried urine spots for doping control purposes

Article

Author: Tsivou, Maria ; Pizzolato, Francesca ; Honesová, Lenka ; Gmeiner, Günter ; Mazzarino, Monica ; Van Eenoo, Peter

Dried urine spots have recently been proposed as an alternative matrix in the anti-doping field. Drying urine may open the opportunity to limit microbial and thermal degradation of the prohibited substances during transportation to the anti-doping laboratories without the need for refrigeration or freezing. In this study, a multi-targeted initial testing procedure was developed for the determination of 237 prohibited drugs/metabolites from 11 different classes in dried urine spots. The comparability between two different microsampling techniques (i.e., Whatman^® FTA DMPK-C cards and Mitra^® tips) was evaluated. The developed method was then used to evaluate the stability of the target compounds in urine for 7 days under different environmental conditions to simulate the transportation of the urine samples from the collection sites to anti-doping laboratories. Sample preparation consists of (i) extraction of the analytes from the collection device using a mixture of acetonitrile/methanol (1/1) for 30 min at 40 °C, (ii) enzymatic hydrolysis, and (iii) sample concentration by solid-phase extraction. Analysis was performed using liquid chromatography coupled to high-resolution mass spectrometry. The entire workflow was validated in terms of specificity (analytes were distinguishable from the matrix interferences), sensitivity (only with the Mitra^® tips the limits of detection comply with the World Anti-Doping Agency's requirements for the majority of the target compounds), carry-over (no signals in the negative urine injected after the positive urine), matrix effect (16-28% for Mitra^® tips and 22-35% for DMPK-C cards), and extraction yield (Mitra^® tips: 51-88%; DMPK-C cards: 40-76%). As proof of concept, authentic urine samples were analyzed: results obtained in dried urine were compared with those of fluid urine, providing good agreement. Stability studies showed that the target compounds were stable for the whole duration of the study (7 days) at -20 and 4 °C in both fluid and dried urine. At 50 °C or at 20-25 °C, several thiazide-based compounds were completely degraded to their degradation product in the first 24 h or after 3-4 days in fluid urine, whereas in dried urine the compounds were detectable for the entire duration of the study.

100 Deals associated with Terbutaline Sulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00688	Terbutaline Sulfate	R03AC03 R03CC03	DB00871

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Bronchial Spasm	China	AstraZeneca Pharmaceuticals Co. Ltd.	01 Jan 1985
Bronchitis	China	AstraZeneca Pharmaceuticals Co. Ltd.	01 Jan 1985
Asthma	Japan	AstraZeneca KK	08 Aug 1973
Asthmatic bronchitis	Japan	AstraZeneca KK	08 Aug 1973
Bronchiectasis	Japan	AstraZeneca KK	08 Aug 1973
Bronchitis, Chronic	Japan	AstraZeneca KK	08 Aug 1973
Pulmonary Emphysema	Japan	AstraZeneca KK	08 Aug 1973

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Eosinophilia, Familial	Phase 1	France	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Phase 1	Sweden	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Phase 1	Germany	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Phase 1	Denmark	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Phase 1	United Kingdom	AstraZeneca PLC	01 May 2005
Eosinophilia, Familial	Phase 1	Spain	AstraZeneca PLC	01 May 2005
Asthma	Phase 1	United States	Sanofi-Aventis U.S. LLC	25 Mar 1974

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03106753 (CTgov)	Phase 4	-	34	Terbutaline+Bupivacaine (Spinal Anesthesia Immediately for ECV.)	zshivfpzsf(qjtquxylst) = jzzvuvrtbn qevfeoxobd (izowlbddnd, hjfpqbadfi - qqwjrrpykf) View more	-	09 Oct 2020
				Terbutaline+Bupivacaine (Spinal Anesthesia if no Intervention Fails for ECV.)	zshivfpzsf(qjtquxylst) = dletkvuhmk qevfeoxobd (izowlbddnd, gklhftrkwr - qltdvvbqay) View more
NCT02224157 (SYGMA2 \| SYGMA 2, CTgov)	Phase 3	Asthma	4,215	Placebo+Symbicort (Placebo Bid + Symbicort 'as Needed' (Experimental))	lkrlbvjhwz(esnijxghoz) = xzyysyynzr vsmwgdtpdj (kdppfwqgra, lxgngdovmc - kdlqzhvlef) View more	-	25 Nov 2019
				Terbutaline+Pulmicort (Pulmicort Bid + Terbutaline 'as Needed' (Active Comparator))	lkrlbvjhwz(esnijxghoz) = ikdvhipfqj vsmwgdtpdj (kdppfwqgra, umlmcgjwgx - fecudwuytf) View more
NCT02149199 (SYGMA1 \| SYGMA 1, CTgov)	Phase 3	Asthma	3,850	Placebo+Symbicort (Placebo Bid + Symbicort 'as Needed')	jruwzegpwv(faffxedkhq) = eenpfiynqs rzwjuuukbh (npaagjzdeg, smoavainex - qlcagvdhox) View more	-	13 Sep 2019
				Placebo+Terbutaline (Placebo Bid + Terbutaline 'as Needed')	jruwzegpwv(faffxedkhq) = lgupziaxuk rzwjuuukbh (npaagjzdeg, jxisosajtm - wfymrawskh) View more
NCT02115256 (CTgov)	Phase 2/3	-	6	Intravenous Terbutaline (Intravenous Terbutaline)	pavcpgykfm(gcbhzbsugd) = qlcehlylip ihxzveodfl (qbfugwycls, kzazijblsh - spkazyxqkx) View more	-	14 Jun 2017
				Intravenous Nitroglycerine (Intravenous Nitroglycerine)	pavcpgykfm(gcbhzbsugd) = fzdvnavukz ihxzveodfl (qbfugwycls, eaacglxckn - odffplhkjr) View more
AAAAI2015	Not Applicable	-	-	Subcutaneous terbutaline	(mgyxmggoiu) = fpyzaftfvn rumwdnjvvt (gaoofnhrau )	Positive	01 Feb 2015
ERS2013	Not Applicable	-	10	Terbutaline	jslfpeyrzg(zojefurbge) = ggqqpkgkpm tzvxtdvxys (mgmsyjyndb ) View more	Positive	01 Sep 2013
				Placebo	jslfpeyrzg(zojefurbge) = kyjlfziakb tzvxtdvxys (mgmsyjyndb ) View more
NCT00839800 (SAKURA, CTgov)	Phase 3	Asthma	2,091	Symbicort Turbuhaler (Symbicort SMART)	lkndycenyb(vwrregupae) = gmlrzurtqe wmlblyykwf (xyqslzpbwm, dvpdnfjfkw - rzqbzyqmxe) View more	-	30 Nov 2012
				Terbutaline+Symbicort (Symbicort+Terbutaline As Needed)	lkndycenyb(vwrregupae) = pypwdiubza wmlblyykwf (xyqslzpbwm, oathbhmfhy - eicftntjeh) View more
NCT00989833 (MIA, CTgov)	Phase 2	Asthma, Exercise-Induced \| Intermittent asthma	66	Terbutaline+Budesonide (Budesonide/Terbutaline)	uieclyzrxt(idpjiduosi) = egyhoqjcrj deianentdy (rnnnvimbpv, hfgxfspuhq - cftobikjqu) View more	-	14 Aug 2012
				Terbutaline (Terbutaline)	uieclyzrxt(idpjiduosi) = iydjeuppfq deianentdy (rnnnvimbpv, bwrbabuenn - sshuoivbvq) View more
NCT00567476 (CTgov)	Phase 4	Persistent asthma	116	Long-acting beta 2-adrenergic agonist (LABA)+terbutaline+salbutamol+Omalizumab (Omalizumab + Conventional Therapy)	lwiwaddtjb(saiyeojzzk) = xnkizsxaxh fltrgsqpio (pndbqolclb, xbmxopzbfv - rukfqzxfga) View more	-	23 May 2011
				Long-acting beta 2-adrenergic agonist (LABA)+terbutaline+salbutamol (Conventional Therapy)	lwiwaddtjb(saiyeojzzk) = uivspqqxwv fltrgsqpio (pndbqolclb, cdiikjjvfz - scdevcjhvt) View more
AAAAI2004	Not Applicable	Asthma	697	Budesonide/formoterol	wgjhybzbpy(fsctchiddu) = uxgzzwafjv opghxptpoe (baaeluamvv ) View more	Positive	01 Feb 2004
				Budesonide plus terbutaline	wgjhybzbpy(fsctchiddu) = ydjwicbsab opghxptpoe (baaeluamvv ) View more